The veterinary vaccines market size was valued at USD 12.12 billion in 2024 and is expected to reach USD 19.06 billion by 2032, growing at a CAGR of 5.84% over 2025-2032.
Get More Information on Veterinary Vaccines Market - Request Sample Report
The veterinary vaccines market is growing at a significant CAGR due to an increase in the prevalence of zoonotic diseases, rising animal health expenditure, the growing incidence of livestock diseases, and the increased adoption of companion animals. Increased awareness of animal health, food safety, and the economic value of preventing diseases in animals is also working in the market's favour. Moreover, there is even more demand being stimulated in public ‘disease eradication’ programmes by governments, e.g., national vaccines. For instance, more than 70% of countries are currently reporting animal diseases to the World Organisation for Animal Health (WOAH), thereby indicating a global focus on veterinary disease surveillance.
In July 2025, Egypt’s new vaccine factory, the MEA region’s largest, seeks to reduce reliance on imports and support regional supply chains for veterinary vaccines, in a sign of movement towards local production and strategic independence.
Significant R&D investment and investments in infrastructure have led to the growth of the veterinary vaccines market, such as the launch of the largest veterinary vaccine production facility in Egypt to cater to the Middle East and Africa. Regulatory support is also strong EMA has recently proposed approval for the first Epizootic Haemorrhagic Disease vaccine, demonstrating favourable regulatory support. Higher investment in R&D, with a focus on recombinant & DNA vaccines, is adding to the veterinary vaccines market statistics, helping manufacturers develop novel products and helping to widen its veterinary vaccines market size by producing new products in different categories.
In July 2025, Qatar and Belarus declared a bilateral cooperation with respect to the development of vaccines and medicine for veterinarians, further strengthening the focus of the world on international vaccination collaboration and distribution in the veterinary vaccines market psychiatry sector.
Table: Emerging Trends in Veterinary Vaccines Market (2023–2025)
|
Trend Description |
Impact on Market |
Key Players/Regions Involved |
|
Surge in DNA and mRNA-based veterinary vaccine research |
Enhancing precision targeting and reducing side effects |
Zoetis, Merck, U.S., Germany |
|
Local manufacturing initiatives in the Middle East & Africa |
Reducing import dependence, boosting regional capacity |
Egypt, UAE, Qatar |
|
Integration of AI and biosensors in livestock vaccination programs |
Improving vaccine deployment and herd health monitoring |
Australia, China |
|
Expansion of companion animal vaccination campaigns |
Boosting demand in urban areas |
India, Brazil |
|
Supply chain disruptions and shortages in veterinary vaccines |
Raising concerns over availability and prompting localisation |
Russia, Eastern Europe |
Market Dynamics:
Drivers:
Rising Disease Burden, Technological Innovation, and Preventive Veterinary Care Fuel Market Expansion
The growth of the veterinary vaccines market is mainly driven by factors such as diseases among animals, increasing animal population and preventive concerns. With more than 60% of human infections of infectious diseases being zoonoses, the demand for animal vaccination has increased to avoid cross-species transmission.
Furthermore, livestock breeders are favouring vaccination to reduce losses and increase productivity, particularly in the poultry and dairy sectors. Emerging vaccine approaches, including viral and subunit vaccines, are receiving growing interest based on improved safety profiles and targeted efficacy. R&D has been attracting higher investment, as firms such as Zoetis and Elanco push the biologics pipeline further.
Global R&D investments in animal health currently surpass USD 1.5 billion per year and are driving innovation. On top of that, regulation has played a critical role in accelerating availability, with, for instance, the USDA’s green light for vaccines for both foot-and-mouth disease and African swine fever serving as evidence of supportive policies. Improved cold chain logistics and increasing veterinary infrastructure in developing nations are causing a demand-supply balance of pork. Moreover, the OIE (World Organisation for Animal Health) supports the use of such data-driven disease surveillance and vaccination strategies, which also augment the veterinary vaccines market growth and veterinary vaccines market size globally.
Restraints:
High Production Costs, Stringent Regulations, and Vaccine Hesitancy Hamper Market Growth
The veterinary vaccines market continues to face a number of challenges and barriers, including high production costs, stringent regulatory pathways, and vaccine reluctance among small-scale farmers. The development and production of vaccines for animals are expenses that must be capitalised and tend to be expenditure-intensive, owing to the complex biology of the pathogens as well as cold chain transportation and compliance with biosafety norms that hold true for human vaccines. Furthermore, stringent safety and efficiency testing is demanded by the authorities (e.g., EMA, USDA, etc.), which elongates the time-to-market by many years.
For instance, it can take 5–8 years to develop a new veterinary vaccine and cost millions before even getting to (or if you ever do) commercialisation. These barriers frequently keep smaller rivals away and stifle innovation. Farmers' wariness to vaccinate, whether due to misinformation, unawareness, or distrust of vaccines, also affects uptake in rural and low-income areas.
Supply-side barriers also limit its accessibility, including insufficient manufacturing capacity for patented vaccines and a challenging refrigeration chain. Trade embargos in times of an outbreak (e.g. avian influenza) frequently lead to interruptions in the supply chain and, as a result, delayed deliveries and immunisation campaigns. Post-market monitoring obligations also contribute to costs and the administrative burden for manufacturers. The combination of all of these factors serves to complicate analysis of the market for veterinary vaccines and impede the dissemination of new and advanced products to underserved markets.
By Product
Based on product, the live attenuated vaccines segment had the biggest share of the veterinary vaccines market in 2024, covering 38.5% of the overall market. The vaccines do provide longer protection and require fewer booster doses, and are therefore more commonly used among veterinarians for cattle and pets. Their ability to manage highly pathogenic emerging diseases, including avian influenza and Newcastle disease, has driven demand. Nevertheless, recombination vaccines were the fastest growing segment owing to their high safety, precision targeting of pathogens, and ability to trace back infections from vaccinated animals (DIVA), particularly in terms of global trade maintenance and disease elimination efforts.
By Animal
By animal type, the livestock segment was the largest in 2024, with 60.3% of the veterinary vaccines market share. This is attributed to high demand for vaccination in cattle, poultry, and swine for food safety, with a decline in economic loss and a surge in meat and dairy product consumption. On the other hand, the companion animal segment is expanding at a rapid pace on account of escalating pet ownership, surging expenditure on pet health and an upsurge in the production of vaccines for dogs and cats.
By Route of Administration
Based on the route of administration, parenteral vaccines dominated the market in 2024 in terms of share. Due to their high bioavailability and accurate dose delivery, they are very well suited for mass vaccination, not least in organised herds and veterinarian environments. At the same time, the oral sector is expanding, based on the convenience of application (in particular in poultry) and increased convenience for pet animals. New encapsulation technology and thermostable oral formulations are also facilitating this pathway.
By Distribution Channel
By distribution channel, veterinary clinics took the lead with a market share of 34.7% in 2024, as they play an essential role in vaccine administration and aftercare. Pharmacies and drug stores are expected to register the fastest growth, due to growing retail presence in urban and semi-urban areas, coupled with rising consumer awareness and over-the-counter distribution of preventive veterinary solutions.
North America was a major revenue contributor in 2024 due to the presence of established veterinary healthcare facilities, a high pet adoption rate, and a large number of livestock.
The U.S. veterinary vaccines market size was valued at USD 4.24 billion in 2024 and is expected to reach USD 6.22 billion by 2032, growing at a CAGR of 4.96% over 2025-2032. The U.S. led the market share in North America on account of a well-developed research infrastructure, regulatory support by the FDA, and rising uptake of advanced vaccines such as DNA and mRNA vaccines. The country presents one of the highest animal vaccination coverage rates in the world, which is a major factor determining the market growth. The U.S. accounted for more than 45% of the regional share in 2024. In addition, an increasing pet-care market and government-funded animal health programs are contributing to the growth in Canada. Mexico is experiencing moderate growth, with rising poultry and cattle farming and growing disease awareness.
Europe is the next largest followed region of the veterinary vaccine market, owing to government initiatives for eradication as well as prevention of animal diseases and a well-established veterinary healthcare infrastructure.
Germany led the European market with high-tech solutions for livestock monitoring, large R&D contribution and government support in the animal health technology space. Additionally, the European Medicines Agency (EMA)’s positive approval process for veterinary biologics takes place, with a significant impact on the availability of products. Following closely are France and the UK, with high levels of pet ownership combined with increased demand for companion animal vaccines. Rising interstate trade of livestock in the EU also supports the demand for vaccination to meet regional biosecurity standards. The EU’s Animal Health Law harmonised vaccine stipulations, reinforcing the efficiency of the production and distribution of vaccines between member states.
The Asia Pacific veterinary vaccines market is projected to be the fastest-growing, owing to the increasing livestock population, growing meat and milk consumption, and governmental support for the prevention of animal diseases.
China is a regional leader through its large livestock population, strong vaccination campaigns and growing investment in local vaccine production capacity. The country recently reported that it has stepped up its vaccine distribution networks in order to cover remote agrarian regions. India is fast growing owing to the presence of a large cattle and poultry sector and the increasing willingness of animal owners for preventive animal healthcare, supported by growing healthcare initiatives in the form of all-over animal vaccination programmes and growing R&D expenditure. Government initiatives such as NADCP (National Animal Disease Control Programme) to accelerate vaccine adoption are propelling the demand for vaccines. Japan and Australia are also contributors, and they share attention to pet health and sophisticated veterinary care systems.
Table: Veterinary Vaccine Shortage and Mitigation Efforts (Selected Countries, 2025)
|
Country |
Nature of Shortage |
Government/Industry Response |
|
Russia |
Acute shortage of veterinary biologics |
Calls for local production boost, expedited imports |
|
South Africa |
Delays in cold chain delivery |
Investment in cold storage infrastructure |
|
Indonesia |
Limited availability of recombinant vaccines |
Public-private partnerships to enhance access |
|
Brazil |
Seasonal surge in livestock immunisation demand |
Pre-positioning of inventory and mobile delivery units |
Leading veterinary vaccines companies in the market include Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim, Virbac, HIPRA, Ceva, NEOGEN, Hester Biosciences, and Phibro Animal Health.
In July 2025, Qatar and Belarus initiated collaborative efforts to locally develop veterinary vaccines and enhance their joint response to animal epidemics, aiming to strengthen regional biosecurity and reduce reliance on imports.
In July 2025, over 500 dogs were vaccinated at NTR Veterinary Hospital in Andhra Pradesh on World Zoonosis Day, highlighting growing awareness and proactive public health measures to prevent zoonotic disease transmission.
In June 2025, Russia reported a severe shortage of animal vaccines, as noted by a leading veterinary association, raising concerns over livestock health and prompting calls for increased domestic production and imports.
| Report Attributes | Details |
| Market Size in 2024 | USD 12.12 billion |
| Market Size by 2032 | USD 19.06 billion |
| CAGR | CAGR of 5.84% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Inactivated, Live Attenuated, Recombinant, and Others) • By Animal (Companion (Feline, Canine, Avian, and Others), Livestock (Poultry, Porcine, Bovine, and Others) • By Route of Administration (Oral, Parenteral, and Others) • By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim, Virbac, HIPRA, Ceva, NEOGEN, Hester Biosciences, and Phibro Animal Health. |
Ans: The estimated compound annual growth rate is 5.84% during the forecast period for the Veterinary Vaccines market.
Ans: The projected market value of the Veterinary Vaccines market is estimated at USD 12.12 Billion in 2023 and is expected to reach USD 19.06 billion by 2032.
Ans: Growing awareness about the importance of animal health and disease prevention is driving the demand for veterinary vaccines.
Ans: High costs can limit the availability and affordability of vaccines, particularly in low-income regions.
Ans: North America is the dominant region in the Veterinary Vaccines market.
Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Animal Disease Incidence and Prevalence, by Region (2024)
5.2 Vaccination Coverage Rates, by Animal Type and Region (2024)
5.3 Veterinary Healthcare Expenditure, by Region and Sector (Government, Private, Livestock Industry) – 2024
5.4 Regulatory Approvals and Product Launches, by Year and Region (2021–2024)
5.5 Immunization Campaigns and Public Health Initiatives (2023–2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Veterinary Vaccines Market Segmentation By Product
7.1 Chapter Overview
7.2 Inactivated
7.2.1 Inactivated Market Trends Analysis (2021-2032)
7.2.2 Inactivated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Live Attenuated
7.3.1 Live Attenuated Market Trends Analysis (2021-2032)
7.3.2 Live Attenuated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Recombinant
7.4.1 Recombinant Market Trends Analysis (2021-2032)
7.4.2 Recombinant Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2021-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Veterinary Vaccines Market Segmentation By Animal
8.1 Chapter Overview
8.2 Companion
8.2.1 Companion Market Trends Analysis (2021-2032)
8.2.2 Companion Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 Feline
8.2.3.1 Feline Market Trends Analysis (2021-2032)
8.2.3.2 Feline Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 Canine
8.2.4.1 Canine Market Trends Analysis (2021-2032)
8.2.4.2 Canine Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.5 Avian
8.2.5.1 Avian Market Trends Analysis (2021-2032)
8.2.5.2 Avian Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.6 Others
8.2.6.1 Others Market Trends Analysis (2021-2032)
8.2.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Livestock
8.3.1 Livestock Market Trends Analysis (2021-2032)
8.3.2 Livestock Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.3 Poultry
8.3.3.1 Poultry Market Trends Analysis (2021-2032)
8.3.3.2 Poultry Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.4 Porcine
8.3.4.1 Porcine Market Trends Analysis (2021-2032)
8.3.4.2 Porcine Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.5 Bovine
8.3.5.1 Bovine Market Trends Analysis (2021-2032)
8.3.5.2 Bovine Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3.6 Others
8.3.6.1 Others Market Trends Analysis (2021-2032)
8.3.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Veterinary Vaccines Market Segmentation By Route of Administration
9.1 Chapter Overview
9.2 Oral
9.2.1 Oral Market Trends Analysis (2021-2032)
9.2.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Parenteral
9.3.1 Parenteral Market Trends Analysis (2021-2032)
9.3.2 Parenteral Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2021-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Veterinary Vaccines Market Segmentation by Distribution Channel
10.1 Chapter Overview
10.2 Veterinary Hospitals
10.2.1 Veterinary Hospitals Market Trends Analysis (2021-2032)
10.2.2 Veterinary Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Veterinary Clinics
10.3.1 Veterinary Clinics Market Trend Analysis (2021-2032)
10.3.2 Veterinary Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Pharmacies & Drug Stores
10.4.1 Pharmacies & Drug Stores Market Trend Analysis (2021-2032)
10.4.2 Pharmacies & Drug Stores Market Size Estimates and Forecasts to 2032 (USD Billion)
10.5 Others
10.5.1 Others Market Trends Analysis (2021-2032)
10.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Veterinary Vaccines Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.2.3 North America Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.4 North America Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.2.5 North America Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.6 North America Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.7.2 USA Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.2.7.3 USA Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.7.4 USA Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.8.2 Canada Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.2.8.3 Canada Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.8.4 Canada Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.2.9.2 Mexico Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.2.9.3 Mexico Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.2.9.4 Mexico Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Veterinary Vaccines Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.3.3 Europe Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.4 Europe Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.5 Europe Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.6 Europe Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.7.2 Germany Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.7.3 Germany Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.7.4 Germany Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.8.2 France Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.8.3 France Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.8.4 France Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.9.2 UK Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.9.3 UK Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.9.4 UK Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 Italy Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.10.2 Italy Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.10.3 Italy Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.10.4 Italy Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.11.2 Spain Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.11.3 Spain Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.11.4 Spain Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.12.2 Poland Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.12.3 Poland Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.12.4 Poland Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.13.2 Turkey Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.13.3 Turkey Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.13.4 Turkey Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.3.14.2 Rest of Europe Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.3.14.3 Rest of Europe Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.3.14.4 Rest of Europe Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Veterinary Vaccines Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.4.3 Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.4 Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.5 Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.6 Asia Pacific Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.7.2 China Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.7.3 China Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.7.4 China Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.8.2 India Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.8.3 India Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.8.4 India Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.9.2 Japan Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.9.3 Japan Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.9.4 Japan Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.10.2 South Korea Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.10.3 South Korea Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.10.4 South Korea Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.11.2 Singapore Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.11.3 Singapore Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.11.4 Singapore Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.12.2 Australia Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.12.3 Australia Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.12.4 Australia Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Veterinary Vaccines Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.5.3 Middle East and Africa Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.4 Middle East and Africa Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.5 Middle East and Africa Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.6 Middle East and Africa Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.7.2 UAE Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.7.3 UAE Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.7.4 UAE Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.8.2 Saudi Arabia Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.8.3 Saudi Arabia Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.8.4 Saudi Arabia Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.9 Qatar
11.5.9.1 Qatar Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.9.2 Qatar Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.9.3 Qatar Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.1.9.4 Qatar Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.10.2 South Africa Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.10.3 South Africa Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.10.4 South Africa Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Veterinary Vaccines Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.6.3 Latin America Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.4 Latin America Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.6.5 Latin America Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.6 Latin America Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.7.2 Brazil Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.6.7.3 Brazil Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.7.4 Brazil Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.8.2 Argentina Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.6.8.3 Argentina Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.8.4 Argentina Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Veterinary Vaccines Market Estimates and Forecasts By Product (2021-2032) (USD Billion)
11.6.9.2 Rest of Latin America Veterinary Vaccines Market Estimates and Forecasts By Animal (2021-2032) (USD Billion)
11.6.9.3 Rest of Latin America Veterinary Vaccines Market Estimates and Forecasts By Route of Administration (2021-2032) (USD Billion)
11.6.9.4 Rest of Latin America Veterinary Vaccines Market Estimates and Forecasts by Distribution Channel (2021-2032) (USD Billion)
12. Company Profiles
12.1 Zoetis
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Elanco
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Merck Animal Health
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Boehringer Ingelheim
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Virbac
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 HIPRA
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Ceva
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 NEOGEN
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Hester Biosciences
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Phibro Animal Health
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Inactivated
Live Attenuated
Recombinant
Others
By Animal
Companion
Feline
Canine
Avian
Others
Livestock
Poultry
Porcine
Bovine
Others
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Veterinary Hospitals
Veterinary Clinics
Pharmacies & Drug Stores
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players